No abstract

Herein we studied the efficiency of a protective transparent and reversible nano silicone wax coatings (NSW) to protect bronze artifacts extracted from Herakleon City, Abu Kir Bay, Alexandria, Egypt. The nano structured silicone wax film resulted in the formation of a structure that can act as a barrier layer from corrosion. The application of NSW coatings on bronze artifacts was evaluated by electrochemical impedance spectroscopy and scanning electron microscopy techniques. Exposure of bronze samples with and without the nano silicone wax coating to sodium chloride solution led to a remarkable inhibition of corrosion for the coated samples only. Comparison of the inhibition efficiency obtained from samples coated with nano silicone wax coatings to that obtained from silicone wax coatings in normal size revealed that the protection efficiency is very high in case of nano silicone wax coatings compared to the traditional silicone wax coatings. The application of nano silicone wax coatings on bronze artifacts can pave the way into the development of safe and tailored solutions in the field of ancient metal artifacts conservation. Graphical abstract

Introduction: In 2015 the historic Jones criteria for the diagnosis of Acute Rheumatic Fever (ARF) were revised introducing two different sets of criteria for low-risk and for moderate/high-risk populations (according to ARF incidence). In Italy the exact ARF incidence is unknown but small regional or local reports suggest an incidence of 2-5/100.000 per year, suggesting that our population might be considered at moderate risk for ARF. Objectives: To evaluate the performance of the revised Jones criteria in a retrospective population and to compare it with the performance of the previous version of Jones criteria. Methods: We conducted a retrospective study on 288 patients with ARF (108 female; median age 8.5 years, IQR 7.1-10.3) diagnosed from 2001 to 2015 in a Pediatric Rheumatology Division by pediatric rheumatologists, discharged with an ICD 9 code consistent with ARF. We retrospectively applied the two sets (for low-risk and for moderate/high-risk) of the 2015 revised Jones criteria and the 1992 version of the Jones criteria. Results: Of 288 patients, 253 (87.8%) met the 1992 version of the Jones criteria, 237 (82.3%) met the revised criteria for low-risk populations and 259 (89.9%) for moderate/high-risk populations. None of these differences was significant. Prevalence of major and minor criteria is shown in Table. With the exception of difference in arthritis, the 1992 version and the 2015 revised version did not show major differences. Of the 288 patients with a clinical diagnosis of ARF 29 did not meet any version of the Jones criteria. Patients in this group presented with isolated chorea or silent carditis without other manifestations. Prevalence of the clinical characteristics and comparison among the 1992 version of Jones criteria and the 2015 revised Jones criteria (low risk and moderate-high risk populations): Values are expressed in Number (percentage). *p value (Fisher Exact test) Conclusion: The revised Jones criteria for low-risk populations are slightly more sensitive than the 1992 version of Jones criteria, while the revised Jones criteria for moderate/high populations are slightly less sensitive than the 1992 version. In this population, the revised criteria did not substantially modify the diagnosis of ARF. Approximately 10% of patients presented with isolated chorea or silent carditis.